Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical Study has reached full enrollment. A ...

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data ...

Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — ...

A guide for finding and unlocking a Fort Storage Room, as well as completing the contracts located there in Sand: Raiders of ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

Summary: A new study demonstrates that the BCG vaccine actively remodels the immune environment surrounding the human brain and spinal cord. By tracking older adults over 12 months, the research team ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. ... Read ...

Researchers have found in a pragmatic cluster-randomized quality improvement trial that asynchronous electronic (e-) screening significantly increased both screening completion rates ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

Campaign Evolved ahead of the July 28th release, marking it Steam Deck Verified / SteamOS Compatible. The rating is now listed on the Steam stor ...

Led by CEO Harry Rowland, VahatiCor is developing the A-Flux coronary sinus reducer implant for coronary microvascular dysfunction.